UnknownPhase 2/3

Letrozole as a Prophylaxis From GTN for Complete Mole Patients

Egypt200 participantsStarted 2020-06-01

Plain-language summary

Prophylactic use of aromatase inhibitor is effective in decreasing the incidence of Gestational Trophoblastic Neoplasia (GTN) in patients with complete hydatidiform mole (CHM)

Who can participate

Age range20 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women were diagnosed to have CHM by ultrasound and confirmed by histopathological examination Exclusion Criteria: * Metastatic disease associated with HM at presentation, in which situation chemotherapy, rather than prophylactic treatment, as prescribed, * Late diagnosis of CHM made only by histological examination of curetted material * Uterine evacuation at another hospital and patient seen at the optimum patient care only for follow up

What they're measuring

(β-hCG) level

Timeframe: at the first day of evacuation

(β-hCG) level

Timeframe: one month after evacuation

(β-hCG) level

Timeframe: two months after evacuation

(β-hCG) level

Timeframe: three months after evacuation

(β-hCG) level

Timeframe: four months after evacuation

(β-hCG) level

Timeframe: Five months after evacuation

(β-hCG) level

Timeframe: Six months after evacuation

Trial details

NCT IDNCT05203562

SponsorZagazig University

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2022-12-01

View on ClinicalTrials.gov More Gestational Trophoblastic Disease trials